Compare Wockhardt with Novartis - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

WOCKHARDT vs NOVARTIS - Comparison Results

WOCKHARDT     Change

Wockhardt is one of the leading domestic pharmaceutical companies with strong presence in the lifestyle segment and a growing focus on biotechnology. While the company made a string of acquisitions in the past namely 'Esparma GmbH' in Germany, 'Pinew... More

NOVARTIS 
   Change

Novartis is a 76% subsidiary of Novartis AG - Switzerland and has a countrywide presence in the healthcare business. While pharmaceuticals contributes 70% to total revenues (FY10), generics (6%), consumer healthcare i.e. OTC (14%) and animal health (... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    WOCKHARDT NOVARTIS WOCKHARDT/
NOVARTIS
 
P/E (TTM) x -18.6 482.3 - View Chart
P/BV x 1.0 28.0 3.5% View Chart
Dividend Yield % 0.0 1.6 0.2%  

Financials

 WOCKHARDT   NOVARTIS
EQUITY SHARE DATA
    WOCKHARDT
Mar-18
NOVARTIS
Mar-18
WOCKHARDT/
NOVARTIS
5-Yr Chart
Click to enlarge
High Rs1,012758 133.5%   
Low Rs532579 91.8%   
Sales per share (Unadj.) Rs355.9228.4 155.8%  
Earnings per share (Unadj.) Rs-60.331.7 -189.9%  
Cash flow per share (Unadj.) Rs-46.832.8 -142.7%  
Dividends per share (Unadj.) Rs0.0110.00 0.1%  
Dividend yield (eoy) %01.5 0.1%  
Book value per share (Unadj.) Rs257.8297.1 86.8%  
Shares outstanding (eoy) m110.6324.69 448.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x2.22.9 74.1%   
Avg P/E ratio x-12.821.1 -60.8%  
P/CF ratio (eoy) x-16.520.4 -80.9%  
Price / Book Value ratio x3.02.2 133.1%  
Dividend payout %031.5 -0.1%   
Avg Mkt Cap Rs m85,37916,505 517.3%   
No. of employees `0006.30.7 936.2%   
Total wages/salary Rs m9,3711,445 648.3%   
Avg. sales/employee Rs Th6,295.08,441.3 74.6%   
Avg. wages/employee Rs Th1,498.32,163.6 69.3%   
Avg. net profit/employee Rs Th-1,066.31,173.1 -90.9%   
INCOME DATA
Net Sales Rs m39,3695,639 698.2%  
Other income Rs m1,2021,718 70.0%   
Total revenues Rs m40,5717,357 551.5%   
Gross profit Rs m18-63 -29.3%  
Depreciation Rs m1,49525 5,910.3%   
Interest Rs m2,55555 4,620.1%   
Profit before tax Rs m-2,8301,575 -179.6%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-3,5820-   
Tax Rs m257792 32.5%   
Profit after tax Rs m-6,669784 -851.0%  
Gross profit margin %0-1.1 -4.2%  
Effective tax rate %-9.150.3 -18.1%   
Net profit margin %-16.913.9 -121.9%  
BALANCE SHEET DATA
Current assets Rs m33,7969,522 354.9%   
Current liabilities Rs m26,9173,296 816.7%   
Net working cap to sales %17.5110.4 15.8%  
Current ratio x1.32.9 43.5%  
Inventory Days Days7937 216.7%  
Debtors Days Days8928 313.9%  
Net fixed assets Rs m39,66446 86,226.2%   
Share capital Rs m553123 448.3%   
"Free" reserves Rs m27,9687,213 387.7%   
Net worth Rs m28,5227,336 388.8%   
Long term debt Rs m21,7310-   
Total assets Rs m81,62011,105 735.0%  
Interest coverage x-0.129.5 -0.4%   
Debt to equity ratio x0.80-  
Sales to assets ratio x0.50.5 95.0%   
Return on assets %-5.07.6 -66.7%  
Return on equity %-23.410.7 -218.9%  
Return on capital %-7.722.2 -34.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m9,80761 16,183.3%   
Fx outflow Rs m1,7893,630 49.3%   
Net fx Rs m8,019-3,570 -224.6%   
CASH FLOW
From Operations Rs m6841,610 42.5%  
From Investments Rs m6,302687 917.4%  
From Financial Activity Rs m-7,695-2,677 287.5%  
Net Cashflow Rs m-664-380 174.9%  

Share Holding

Indian Promoters % 74.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 2.3 2.0 115.0%  
FIIs % 7.7 1.6 481.3%  
ADR/GDR % 0.1 0.0 -  
Free float % 15.4 21.5 71.6%  
Shareholders   67,757 41,647 162.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare WOCKHARDT With:   PROCTER & GAMBLE HEALTH  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare WOCKHARDT With:   ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  MYLAN (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Opens Marginally Higher; Energy & Realty Stocks Lead(09:30 am)

Asian share markets are higher today as Britain and the EU made headway on a Brexit deal ahead of a leaders' summit.

Related Views on News

WOCKHARDT Announces Quarterly Results (1QFY20); Net Profit Up 57.2% (Quarterly Result Update)

Aug 28, 2019 | Updated on Aug 28, 2019

For the quarter ended June 2019, WOCKHARDT has posted a net profit of Rs 369 m (up 57.2% YoY). Sales on the other hand came in at Rs 9 bn (down 14.3% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

NOVARTIS Announces Quarterly Results (1QFY20); Net Profit Down 92.1% (Quarterly Result Update)

Aug 13, 2019 | Updated on Aug 13, 2019

For the quarter ended June 2019, NOVARTIS has posted a net profit of Rs 8 m (down 92.1% YoY). Sales on the other hand came in at Rs 1 bn (down 20.8% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

NOVARTIS Announces Quarterly Results (4QFY19); Net Profit Down 26.2% (Quarterly Result Update)

May 30, 2019 | Updated on May 30, 2019

For the quarter ended March 2019, NOVARTIS has posted a net profit of Rs 195 m (down 26.2% YoY). Sales on the other hand came in at Rs 1 bn (down 11.9% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

WOCKHARDT Announces Quarterly Results (4QFY19); Net Profit Up 90.8% (Quarterly Result Update)

May 7, 2019 | Updated on May 7, 2019

For the quarter ended March 2019, WOCKHARDT has posted a net profit of Rs 139 m (up 90.8% YoY). Sales on the other hand came in at Rs 10 bn (down 3.8% YoY). Read on for a complete analysis of WOCKHARDT's quarterly results.

NOVARTIS Announces Quarterly Results (3QFY19); Net Profit Down 31.3% (Quarterly Result Update)

Feb 13, 2019 | Updated on Feb 13, 2019

For the quarter ended December 2018, NOVARTIS has posted a net profit of Rs 129 m (down 31.3% YoY). Sales on the other hand came in at Rs 1 bn (down 13.1% YoY). Read on for a complete analysis of NOVARTIS's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Finally, Is the Share Price of Yes Bank Ready for a Rebound?(The 5 Minute Wrapup)

Oct 7, 2019

Here's what every individual investor must know about Yes Bank...

Rebound Riches Could be Yours With These Stocks(Profit Hunter)

Oct 4, 2019

The secret to multibagger is not big businesses, but great managements... Here's how to find them to make the most of once in a decade rebound opportunity.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

WOCKHARDT SHARE PRICE


Oct 16, 2019 11:09 AM

TRACK WOCKHARDT

  • Track your investment in WOCKHARDT with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

WOCKHARDT 8-QTR ANALYSIS

COMPARE WOCKHARDT WITH

MARKET STATS